Sanguis Dx is developing an innovative Point-of-Care diagnostic platform that enables rapid, ultrasensitive and quantitative measurements of biomarkers in finger-prick blood and saliva.

system features

Lead indication

Preeclampsia & Pregnancy Complications

  • Preeclampsia is a leading cause of infant/maternal death worldwide and leading cause of preterm births. 

  • Rapid and accurate testing at the Point-of-Care is critical to triage suspected preterm

  • Global market valued at $2.16 billion (diagnostic segment) with further potential for substantial growth in screening segment (>200 million pregnancies per year)

other indications

Ultrahigh sensitivity and broad dynamic range vs current point-of-care biomarker testing technologies enable us to target unserved diagnostic indications.

Heart Failure: Diagnosis & Management

Lifetime risk for Heart Failure > 20% beyond middle age

Our technology uniquely addresses the critical need for better diagnosis and management of heart failure through better HF biomarker testing

Heart failure global market predicted to reach $16 billion by 2026

Infectious Diseases &  Covid-19

Sanguis Dx technology is ideally positioned to enable ultrasensitive "point-of-need / at-home"  testing within 30 minutes

Traumatic Brain Injury & Concussion 

Approximately 69 million people suffer from Traumatic Brain Injury each year and TBI is the leading cause of injury-related death and disability 

Biomarkers for objective assessment of TBI and its recovery are now available

We aim to enable better management of mild TBI through point-of-care testing

Traumatic brain injury diagnostic market valued at $2.9 billion

The team

Prof Benjamin Thierry


Dr Duy Tran


Dr JC Tan

Head of Business Development

Board of advisor

Dr Michael Crouch

Technology & Bioassay Advisor

Stewart Bartlett

Business Advisor


Contact us

Get in touch with us for more information:
Name E-mail  Message I agree to the Terms & Conditions and Privacy Policy Submit